AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus
NCT ID: NCT00241605
Last Updated: 2018-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
600 participants
INTERVENTIONAL
2003-06-25
2005-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin
NCT00386100
Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)
NCT00131664
AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes
NCT00359112
A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)
NCT00511667
Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs
NCT00491725
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rosiglitazone/metformin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have stopped previous treatment with thiazolidinediones or other anti-diabetic agents at least 3 months prior to screening.
* Women must be post-menopausal, surgically sterile or using acceptable contraceptive measures.
Exclusion Criteria
* Have a known hypersensitivity to thiazolidinediones or biguanides.
* Currently using insulin or any oral anti-diabetic agent other than metformin.
* History of metabolic acidosis.
* History of substance abuse.
* Have active cancer other than localized squamous or basal cell carcinoma.
* Chronic disease requiring treatment with corticosteroids.
* Other criteria will be evaluated at the screening visit.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Medicine Hat, Alberta, Canada
GSK Investigational Site
Aldergrove, British Columbia, Canada
GSK Investigational Site
Kelowna, British Columbia, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Fredericton, New Brunswick, Canada
GSK Investigational Site
Houston, New Brunswick, Canada
GSK Investigational Site
Neguac, New Brunswick, Canada
GSK Investigational Site
Bay Roberts, Newfoundland and Labrador, Canada
GSK Investigational Site
Carbonear, Newfoundland and Labrador, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site
Dartmouth, Nova Scotia, Canada
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Truro, Nova Scotia, Canada
GSK Investigational Site
Upper Tantallon, Nova Scotia, Canada
GSK Investigational Site
Ajax, Ontario, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Burlington, Ontario, Canada
GSK Investigational Site
Cambridge, Ontario, Canada
GSK Investigational Site
Fort Erie, Ontario, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
Innisfil, Ontario, Canada
GSK Investigational Site
Kingston, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Mississauga, Ontario, Canada
GSK Investigational Site
Mississauga, Ontario, Canada
GSK Investigational Site
North York, Ontario, Canada
GSK Investigational Site
Oakville, Ontario, Canada
GSK Investigational Site
Oshawa, Ontario, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Peterborough, Ontario, Canada
GSK Investigational Site
Rexdale, Ontario, Canada
GSK Investigational Site
Richmond Hill, Ontario, Canada
GSK Investigational Site
Scarborough Village, Ontario, Canada
GSK Investigational Site
Scarborough Village, Ontario, Canada
GSK Investigational Site
Smiths Falls, Ontario, Canada
GSK Investigational Site
Sutton, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Windsor, Ontario, Canada
GSK Investigational Site
Woodbridge, Ontario, Canada
GSK Investigational Site
Woodstock, Ontario, Canada
GSK Investigational Site
Woodstock, Ontario, Canada
GSK Investigational Site
Brossard, Quebec, Canada
GSK Investigational Site
Charlesbourg, Quebec, Canada
GSK Investigational Site
Charlesbourg, Quebec, Canada
GSK Investigational Site
Châteauguay, Quebec, Canada
GSK Investigational Site
Courcelette, Quebec, Canada
GSK Investigational Site
Cowansville, Quebec, Canada
GSK Investigational Site
Hull, Quebec, Canada
GSK Investigational Site
Lambton, Quebec, Canada
GSK Investigational Site
Lle Perrot, Quebec, Canada
GSK Investigational Site
Longueuil, Quebec, Canada
GSK Investigational Site
Longueuil, Quebec, Canada
GSK Investigational Site
Longueuil, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Pierrefonds, Quebec, Canada
GSK Investigational Site
Pointe-Claire, Quebec, Canada
GSK Investigational Site
Richelieu, Quebec, Canada
GSK Investigational Site
Saint-Charles-Borromée, Quebec, Canada
GSK Investigational Site
Saint-Jean-sur-Richelieu, Quebec, Canada
GSK Investigational Site
Saint-Léonard, Quebec, Canada
GSK Investigational Site
Sainte-Anne-de-Bellevue, Quebec, Canada
GSK Investigational Site
Sainte-Catherine, Quebec, Canada
GSK Investigational Site
Sainte-Foy, Quebec, Canada
GSK Investigational Site
Sainte-Henri de Levis, Quebec, Canada
GSK Investigational Site
Salaberry-de-Valleyfield, Quebec, Canada
GSK Investigational Site
Thetford-Mines, Quebec, Canada
GSK Investigational Site
Vaudreuil, Quebec, Canada
GSK Investigational Site
Ville Lasalle, Quebec, Canada
GSK Investigational Site
Saskatoon, Saskatchewan, Canada
GSK Investigational Site
Saskatoon, Saskatchewan, Canada
GSK Investigational Site
Saskatoon, Saskatchewan, Canada
GSK Investigational Site
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
712753/008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.